MannKind (MNKD) News & Sentiment

MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22

Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

MannKind (MNKD) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.02 per share a year ago.

2024 revenues of $286M, +43% v. 2023; 4Q 2024 revenues of $77M, +31% v.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focusing on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Dominic Marasco, RPh, has joined the company as President, Endocrine Business Unit, effective January 6, 2025.

Company plans to meet with FDA regarding potential sNDA submission in 1H 2025 Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression DANBURY, Conn.

India has the 2 nd highest burden of diabetes worldwide CDSCO decision follows existing approvals in the U.S.A. and Brazil MannKind expects to ship product for Cipla Ltd.

MannKind (MNKD) came out with quarterly earnings of $0.04 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.02 per share a year ago.